Your browser doesn't support javascript.
loading
Local control and survival after stereotactic radiosurgery for colorectal cancer brain metastases: an international multicenter analysis.
Bin-Alamer, Othman; Abou-Al-Shaar, Hussam; Singh, Raj; Mallela, Arka N; Legarreta, Andrew; Bowden, Greg; Mathieu, David; Perlow, Haley K; Palmer, Joshua D; Elhamdani, Shahed; Shepard, Matthew; Liang, Yun; Nabeel, Ahmed M; Reda, Wael A; Tawadros, Sameh R; Abdelkarim, Khaled; El-Shehaby, Amr M N; Emad Eldin, Reem; Elazzazi, Ahmed Hesham; Warnick, Ronald E; Gozal, Yair M; Daly, Megan; McShane, Brendan; Addis-Jackson, Marcel; Karthikeyan, Gokul; Smith, Sian; Picozzi, Piero; Franzini, Andrea; Kaisman-Elbaz, Tehila; Yang, Huai-Che; Hess, Judith; Templeton, Kelsey; Zhang, Xiaoran; Wei, Zhishuo; Pikis, Stylianos; Mantziaris, Georgios; Simonova, Gabriela; Liscak, Roman; Peker, Selcuk; Samanci, Yavuz; Chiang, Veronica; Kersh, Charles R; Lee, Cheng-Chia; Trifiletti, Daniel M; Niranjan, Ajay; Hadjipanayis, Constantinos G; Lunsford, L Dade; Sheehan, Jason P.
Afiliación
  • Bin-Alamer O; 1Department of Neurological Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.
  • Abou-Al-Shaar H; 1Department of Neurological Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.
  • Singh R; 2Department of Radiation Oncology, Virginia Commonwealth University Health System, Richmond, Virginia.
  • Mallela AN; 1Department of Neurological Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.
  • Legarreta A; 1Department of Neurological Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.
  • Bowden G; 3Department of Neurosurgery, University of Alberta, Edmonton, Alberta, Canada.
  • Mathieu D; 4Department of Neurosurgery, Université de Sherbrooke, Quebec, Canada.
  • Perlow HK; Departments of5Radiation Oncology and.
  • Palmer JD; Departments of5Radiation Oncology and.
  • Elhamdani S; 6Neurosurgery, The James Cancer Hospital and Solove Research Institute, Ohio State University Wexner Medical Center, Columbus, Ohio.
  • Shepard M; Departments of7Neurosurgery and.
  • Liang Y; Departments of7Neurosurgery and.
  • Nabeel AM; 8Radiation Oncology, Allegheny Health Network, Pittsburgh, Pennsylvania.
  • Reda WA; 9Gamma Knife Center, Nasser Institute Hospital, Cairo, Egypt.
  • Tawadros SR; 10Department of Neurosurgery, Benha University, Benha, Egypt.
  • Abdelkarim K; 9Gamma Knife Center, Nasser Institute Hospital, Cairo, Egypt.
  • El-Shehaby AMN; Departments of11Neurosurgery and.
  • Emad Eldin R; 9Gamma Knife Center, Nasser Institute Hospital, Cairo, Egypt.
  • Elazzazi AH; Departments of11Neurosurgery and.
  • Warnick RE; 9Gamma Knife Center, Nasser Institute Hospital, Cairo, Egypt.
  • Gozal YM; 12Clinical Oncology, Ain Shams University, Cairo, Egypt.
  • Daly M; 9Gamma Knife Center, Nasser Institute Hospital, Cairo, Egypt.
  • McShane B; Departments of11Neurosurgery and.
  • Addis-Jackson M; 9Gamma Knife Center, Nasser Institute Hospital, Cairo, Egypt.
  • Karthikeyan G; 13Department of Radiation Oncology, National Cancer Institute, Cairo University, Cairo, Egypt.
  • Smith S; 14Ain Shams University, Cairo, Egypt.
  • Picozzi P; 15Gamma Knife Center, Jewish Hospital, Mayfield Clinic, Cincinnati, Ohio.
  • Franzini A; 15Gamma Knife Center, Jewish Hospital, Mayfield Clinic, Cincinnati, Ohio.
  • Kaisman-Elbaz T; 16Department of Neurosurgery, University of Pennsylvania, Philadelphia, Pennsylvania.
  • Yang HC; 16Department of Neurosurgery, University of Pennsylvania, Philadelphia, Pennsylvania.
  • Hess J; 16Department of Neurosurgery, University of Pennsylvania, Philadelphia, Pennsylvania.
  • Templeton K; 16Department of Neurosurgery, University of Pennsylvania, Philadelphia, Pennsylvania.
  • Zhang X; 16Department of Neurosurgery, University of Pennsylvania, Philadelphia, Pennsylvania.
  • Wei Z; 17Department of Neurosurgery, Humanitas Research Hospital-IRCCS, Milan, Italy.
  • Pikis S; 17Department of Neurosurgery, Humanitas Research Hospital-IRCCS, Milan, Italy.
  • Mantziaris G; 18Rose Ella Burkhart Brain Tumor and Neuro-Oncology Center, Neurological Institute, Cleveland Clinic, Cleveland, Ohio.
  • Simonova G; 19Department of Neurosurgery, Neurological Institute, Taipei Veterans General Hospital, Taipei, Taiwan.
  • Liscak R; 20National Yang Ming Chiao Tung University School of Medicine, Hsinchu, Taiwan.
  • Peker S; 21Department of Neurosurgery, Yale University School of Medicine, New Haven, Connecticut.
  • Samanci Y; 21Department of Neurosurgery, Yale University School of Medicine, New Haven, Connecticut.
  • Chiang V; 1Department of Neurological Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.
  • Kersh CR; 1Department of Neurological Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.
  • Lee CC; Departments of22Neurological Surgery and.
  • Trifiletti DM; Departments of22Neurological Surgery and.
  • Niranjan A; 23Department of Stereotactic and Radiation Neurosurgery, Na Homolce Hospital, Prague, Czech Republic.
  • Hadjipanayis CG; 23Department of Stereotactic and Radiation Neurosurgery, Na Homolce Hospital, Prague, Czech Republic.
  • Lunsford LD; 24Department of Neurosurgery, Koc University School of Medicine, Istanbul, Turkey; and.
  • Sheehan JP; 24Department of Neurosurgery, Koc University School of Medicine, Istanbul, Turkey; and.
J Neurosurg ; : 1-10, 2023 Nov 10.
Article en En | MEDLINE | ID: mdl-37948682
ABSTRACT

OBJECTIVE:

The goal of this study was to characterize local tumor control (LC), overall survival (OS), and safety of stereotactic radiosurgery for colorectal brain metastasis (CRBM).

METHODS:

Ten international institutions participating in the International Radiosurgery Research Foundation provided data for this retrospective case series. This study included 187 patients with CRBM (281 tumors), with a median age of 62 years and 56.7% being male. Most patients (53.5%) had solitary tumors, although 10.7% had > 5 tumors. The median tumor volume was 2.7 cm3 (IQR 0.22-8.1 cm3), and the median margin dose was 20 Gy (IQR 18-22 Gy).

RESULTS:

The 3-year LC and OS rates were 72% and 20%, respectively. Symptomatic adverse radiation effects occurred in 1.6% of patients. In the multivariate analysis, age > 65 years and tumor volume > 4.0 cm3 were significant predictors of tumor progression (hazard ratio [HR] 2.6, 95% CI 1.4-4.9; p = 0.003 and HR 3.4, 95% CI 1.7-6.9; p < 0.001, respectively). Better performance status (Karnofsky Performance Scale score > 80) was associated with a reduced risk of tumor progression (HR 0.38, 95% CI 0.19-0.73; p = 0.004). Patient age > 62 years (HR 1.6, 95% CI 1.1-2.3; p = 0.03) and the presence of active extracranial disease (HR 1.7, 95% CI 1.1-2.4; p = 0.009) were significantly associated with worse OS.

CONCLUSIONS:

Stereotactic radiosurgery offers a high LC rate and a low rate of symptomatic adverse radiation effects for the majority of CRBMs. The OS and LC favored younger patients with high functional performance scores and inactive extracranial disease.
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: J Neurosurg Año: 2023 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: J Neurosurg Año: 2023 Tipo del documento: Article